Find more clinical trials

Aspirin in Reducing Events in the Elderly (ASPREE)

Start: January 2010

End: April 2024

Enrollment: 19000

What Is This Study About?

The ASPREE study will examine whether the potential benefits of low-dose aspirin (particularly preventing heart disease, stroke, certain cancers, and dementia) outweigh the risks (particularly bleeding) in people over age 70. ASPREE will determine whether taking a daily low-dose aspirin will extend the length of a disability-free life in healthy participants aged 70 years and above.

Do I Qualify To Participate in This Study?

Minimum Age: 70 Years

Must have:

++Men and women 70 years of age and over

Must NOT have:

++History of a diagnosed cardiovascular event++Serious intercurrent illness likely to cause death within the next 5 years, such as terminal cancer or obstructive airways disease++Current or recurrent condition with a high risk of major bleeding, for example, cerebral aneurysm++Anemia++Current participation in a clinical trial++Systolic blood pressure of ≥180 mmHg and/or diastolic blood pressure of ≥105 mmHg++History of dementia++Severe difficulty or inability to perform any one of the 6 Katz activities of daily living++Noncompliance to taking pill++Absolute contraindication or allergy to aspirin++Current continuous use of aspirin or other antiplatelet drug or anticoagulant for secondary prevention; people with previous use of aspirin for primary prevention may enter the trial, provided they agree to cease existing use of aspirin and understand that they may be subsequently randomly allocated to low-dose aspirin or placebo

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Who Is the General Study Contact?

If you are interested in joining ASPREE, please contact a location near you from the list below. For more information about this trial, visit the ASPREE website.

Where Is This Study Located?

The University of Alabama at Birmingham
Birmingham, 35294
Palo Alto Medical Foundation Research Institute
Palo Alto, 94301
District of Columbia
Howard University
Washington, 20060
University of Florida Department of Aging and Geriatrics
Gainesville, 32611
Morehouse School of Medicine
Atlanta, 30310
Emory/ Atlanta VAMC
Atlanta, 30322
Georgia Health Sciences University
Augusta, 30912
Rush Alzheimer's Disease Center
Chicago, 60612
University of Iowa
Iowa City, 52242
Kansas University Medical Center
Kansas City, 66106
Pennington Biomedical Research Center
Baton Rouge, 70808
Mary Bird Perkins Our Lady of the Lake Cancer Center
Baton Rouge, 70809
LSU Health Sciences- New Orleans
New Orleans, 70112
Tulane Medical Center
New Orleans, 70112
LSU Health Sciences- Shreveport
Shreveport, 71130
University of Michigan
Ann Arbor, 48109
Wayne State University
Detroit, 48201
Henry Ford Health System
Detroit, 48202
Detroit Clinical Research Center
Novi, 48377
Health Partners Research Foundation
Minneapolis, 55425
Phalen Village Clinic
Saint Paul, 55106
New Jersey
Central Jersey Medical Center
Elizabeth, 07202
New York
Winthrop University Hospital
Mineola, 11501
North Carolina
Wake Forest University Baptist Medical Center
Greensboro, 27408
The Brody School of Medicine at ECU
Greenville, 27834
Albert Einstein Medical Center
Philadelphia, 19141
University of Pittsburgh Health Sciences Research Center
Pittsburgh, 15260
Rhode Island
Memorial Hospital of Rhode Island
Pawtucket, 02860
University of Tennessee Health Science Center
Memphis, 38105
University of Texas Southwestern Medical Center at Dallas
Dallas, 75390
University of TX Medical Branch
Galveston, 77555
Regional Academic Health Center
Harlingen, 78550
UT Health Science Center at San Antonio
San Antonio, 78229

Who Sponsors This Study?

Lead: Minneapolis Medical Research Foundation

Source: ID: NCT01038583